Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
This study will be conducted with the aim of investigating the efficacy, safety and
 tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active
 comparator (venlafaxine extended release 150 mg/day).
Inclusion Criteria:

 -  The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™
 criteria. The current Major Depressive Episode (MDE) should be confirmed using the
 Mini International Neuropsychiatric Interview (MINI)

 -  The patient has a MADRS total score ≥26

 -  The patient has a CGI-S score ≥4

 -  The reported duration of the current MDE is ≥3 months.

 Other inclusion criteria may apply.

 Exclusion Criteria:

 - The patient meets any of the exclusion criteria listed in the protocol or, in the
 investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any
 reason.